Navigation Links
Doctor Grilled In Court For False Report About Vioxx Health Risk

The doctor, who had dismissed increased risk of heart attack associated with Vioxx, has been accused by lawyers who argue that his views are 'out of the mainstream' as it is based on biased research //, funded by the drug company, Merck and Co.

Thomas Cona and John Mcdarby have sued the pharmaceutical company, stating that use of the drug had resulted in heart attacks. More than 10, 000 different lawsuits has been filed against the controversial Vioxx, on grounds of product liability. The product, originally intended for arthritis treatment was withdrawn from the market in the September of 2004.

The case was taken up for hearing recently. Attorney Mark Lanier questioned the motivation and educational qualifications of Merck expert witness Dr. Barry Rayburn during the cross-examination. He works as a cardiologist in the University of Alabama. He further stated that anyone who had not taken money from Merck would deserve to be called mainstream doctor.

The attorney who stands for Thomas Cona is the only who had won a case against Merck, last August. He enabled a Texas based widow, a user of Vioxx receive a multimillion-dollar jury award. Other similar trials that were taken up in the state and federal courts had ended up in favor of Merck.

Rayburn was peppered with questions about studies and articles that demonstrated an increased risk of heart attack in those who used Vioxx. This however was not included in the doctor’s testimony that was submitted in the court on Tuesday. To this Rayburn responded by saying that some of the articles or studies cited by Lanier were not included in his testimony because he 'felt it was important to look at things that were peer reviewed. I also looked at many studies we have not talked about'.

The close scrutiny by several other experts in a specific field confers the peer-reviewed studies, a higher credibility. Every attempt is made to ensure that the study was indeed desig ned and conducted in a systematic way, to meet the industry standards. The cardiologist pointed out to the study conducted on more than 28, 000 patients that had no evidence of increased heart attack or other cardiovascular complications.

In addition, Rob Gordon, a lawyer representing McDarby, grilled Rayburn about his legal work for Merck, his payment and involvement in other clinical trials conducted by the drug company.

Following a study, which showed for the first time that use of the drug for a period of 18 months, doubled the heart attack risk; the pain relief was withdrawn from the drug market.

The conclusion, according to the lawyers is that although it was known that the drug increased risk of heart attacks in users, the drug company failed to warn the users, compromising on patient safety for want of profit.


Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Doctors needed urgently in Gujarat
3. Doctors operate upon patients in candlelight- latest from the quake scene
4. Doctors at risk- the ugly side of the noble profession
5. Doctors advice early anemia tests
6. Indian Doctor granted US patent on organ regeneration
7. Emphasis to ban Drugs ads by Doctors
8. Doctor samples come under the ambit of advertisement
9. Doctors not to accept gifts from drug companies
10. Gene testing kit specific for Doctors
11. Doctors warned of fluoride toxicity
Post Your Comments:

(Date:11/27/2015)... Minn. (PRWEB) , ... November 27, 2015 , ... ... start failing. Secura Consultants has prided itself for not only fulfilling the needs ... income protection solutions at an affordable price and providing top-tier customer service. However, ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... most successful and prominent nonprofit healthcare organizations in the country. They have overseen ... various organizations, and helped advance the healthcare industry as a whole through their ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... contact center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term ... fully supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical ... professionals and offered by healthcare staffing agency Aureus Medical Group . ... of October 2015 among those searching for healthcare jobs through the company’s website, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
Breaking Medicine Technology: